You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Foundayo ™ (orforglipron) tablet
0.8 mg / 2.5 mg / 5.5 mg / 9 mg / 14.5 mg / 17.2 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Should Foundayo™ (orforglipron) therapy be modified for surgical procedures or hospitalization?
The use of orforglipron in patients undergoing surgical procedures or hospitalization has not been evaluated. Instruct patients to inform healthcare providers of any planned surgeries or procedures.
See important safety information, including boxed warning, in the attached prescribing information.
Content Overview
- Can Orforglipron Be Used in the Hospital or Surgical Setting?
- What are the Pharmacokinetics of Orforglipron?
- Enclosed Prescribing Information
- Reference
Can Orforglipron Be Used in the Hospital or Surgical Setting?
The use of orforglipron in patients undergoing surgical procedures or hospitalization has not been evaluated.
Orforglipron delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving glucagon-like peptide-1 (GLP-1) receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.1
Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking orforglipron, including whether modifying preoperative fasting recommendations or temporarily discontinuing orforglipron could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking orforglipron.1
Healthcare providers should use patient medical records and their clinical judgment to make a treatment recommendation. The additional considerations discussed in this document may be helpful to determine what is best for their patient.
What are the Pharmacokinetics of Orforglipron?
The maximum concentration of orforglipron is reached 4 to 8 hours post dose. Orforglipron tablet exposure increases in a dose-proportional manner. The geometric mean absolute bioavailability of orforglipron was 77% after a 0.8 mg dose.1
No clinically relevant effect of food on orforglipron exposure was observed. Orforglipron can be taken with or without food.1
The mean steady-state volume of distribution of orforglipron is approximately 285 L, following intravenous dosing in healthy subjects. Orforglipron plasma protein binding is greater than 99%.1
The mean systemic clearance of orforglipron is 7.15 L/hour. The elimination half-life is approximately 29 to 49 hours after an oral dose, enabling daily administration. Steady state exposure is achieved after approximately 1 week of once daily administration.1
After administration of a single oral dose of 2.5 mg orforglipron, 87% of the dose was recovered in feces (all metabolites) and less than 1% of the dose was recovered in urine.1
Enclosed Prescribing Information
FOUNDAYO™ (orforglipron) tablets, for oral use, Lilly
Reference
- Foundayo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
Date of Last Review: April 03, 2026